Acute Coronary Syndrome - A Pipeline Analysis Report

Overview of the drug development for acute coronary syndrome

Acute coronary syndrome (ACS) impacts the functioning of the heart due to the insufficient supply of blood in the coronary arteries. Atherosclerosis, a buildup of plaque in the coronary arteries, is a major cause of ACS. ACS is consequent in high mortality rates among younger people and in and low and middle-income countries. ACS includes ST-elevation myocardial infarction (STEMI), non-STEMI, and unstable angina. This disease also results in mortality and disability in APAC. Technavio’s market research analysts have predicted that with the introduction of the 12-lead electrocardiogram, as one of the most common diagnostic approaches to treat coronary syndromes, acute coronary syndrome market worth will increase in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are in the Phase III development stage and a considerable number of molecules are being evolved for better results.

Acute coronary syndrome market worth: Companies covered

According to the acute coronary syndrome market forecast, this pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for acute coronary syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report

• Dexa Medica
• GlaxoSmithKline
• Novartis

Therapeutic assessment of the drug development pipeline for acute coronary syndrome by route of administration

• IV
• Oral
• Subcutaneous

The intravitreal route of administration (ROA) involves the application of the drug directly onto the vitreous fluid and in the subretinal technique, the molecules are applied to the subretinal space, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for acute coronary syndrome by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for acute coronary syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development for monotherapy.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for acute coronary syndrome?
• What are the companies that are currently involved in the development of drug development for acute coronary syndrome?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.